학술논문
Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer
Document Type
article
Author
Source
Nature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
Subject
Language
English
ISSN
2041-1723
Abstract
Resistance to endocrine treatment in ER+/HER2- breast cancer patients remains a significant clinical problem. Here, the authors demonstrate that loss of the MutL mismatch repair complex can serve as a first-in-class predictive biomarker for combinatorial inhibition of HER2 to overcome the emergence of endocrine treatment resistance.